Total Holdings
33
Portfolio diversification across 33 positions
PBE
(NYSEARCA)Invesco Biotechnology & Genome ETF
$85.44-- (--)
Loading... - Market loading
PBE ETF Holdings: Invesco Biotechnology & Genome ETF
Complete portfolio holdings with allocation weights, sector breakdown, and geographic exposure for this Equity ETF. Analyze fund diversification and concentration.
Assets Under Management
$257.89M
Total fund assets
Expense Ratio
0.58%
Annual management fee
Fund Issuer
Invesco
NYSEARCA
Portfolio Allocations
Distribution breakdown by sector, asset type, and geographic region. Understand the fund's diversification strategy across markets and asset classes.
Loading chart...
Top 32 Holdings by Portfolio Weight
View ticker symbols, company names, asset types, and allocation percentages for each position
Scroll to see more
| # | Symbol | Name | Type | Weight |
|---|---|---|---|---|
| 1 |  | Amgen Inc | Stock | 5.11% |
| 2 |  | Biogen Inc | Stock | 5.02% |
| 3 |  | Vertex Pharmaceuticals Incorporated | Stock | 5.00% |
| 4 |  | Royalty Pharma plc | Stock | 4.98% |
| 5 |  | Alnylam Pharmaceuticals, Inc | Stock | 4.75% |
| 6 |  | Regeneron Pharmaceuticals, Inc. | Stock | 4.69% |
| 7 |  | United Therapeutics Corporation | Stock | 4.60% |
| 8 |  | Gilead Sciences, Inc | Stock | 4.56% |
| 9 |  | Legend Biotech Corporation | Stock | 3.25% |
| 10 |  | Bio-Techne Corporation | Stock | 3.09% |
| 11 |  | Repligen Corporation | Stock | 3.06% |
| 12 |  | Illumina, Inc. | Stock | 3.03% |
| 13 |  | PTC Therapeutics, Inc. | Stock | 3.00% |
| 14 |  | Protagonist Therapeutics, Inc. | Stock | 2.97% |
| 15 |  | CareDx, Inc. | Stock | 2.95% |
| 16 |  | Veracyte, Inc. | Stock | 2.94% |
| 17 |  | Incyte Corporation | Stock | 2.94% |
| 18 |  | Vericel Corporation | Stock | 2.92% |
| 19 |  | Exelixis, Inc | Stock | 2.83% |
| 20 |  | BioCryst Pharmaceuticals, Inc. | Stock | 2.82% |
| 21 | E ETR:QIA | QIAGEN N.V | Stock | 2.78% |
| 22 |  | BioMarin Pharmaceutical Inc. | Stock | 2.78% |
| 23 |  | Neurocrine Biosciences, Inc | Stock | 2.76% |
| 24 |  | Qiagen N.V. | Stock | 2.75% |
| 25 |  | Halozyme Therapeutics, Inc. | Stock | 2.74% |
| 26 |  | AnaptysBio, Inc. | Stock | 2.72% |
| 27 |  | Collegium Pharmaceutical Inc | Stock | 2.69% |
| 28 |  | ACADIA Pharmaceuticals Inc | Stock | 2.66% |
| 29 |  | Ardelyx, Inc | Stock | 2.45% |
| 30 |  | Sarepta Therapeutics, Inc | Stock | 2.38% |
| 31 |  | Omeros Corporation | Stock | 2.31% |
| 32 | N NMFQS:AGPXX | Short-Term Investment Trust - Invesco Government & Agency Portfolio | Cash | 0.17% |
Frequently Asked Questions About Invesco Biotechnology & Genome ETF Holdings
What are the top holdings in PBE?
Invesco Biotechnology & Genome ETF (PBE) holds 33 securities. View the complete list of top holdings sorted by portfolio weight, showing each security's ticker symbol, company name, asset type, and allocation percentage.
How concentrated is PBE's portfolio?
Portfolio concentration is measured by the weight of top holdings. A concentrated portfolio has fewer large positions with higher individual weights, while a diversified portfolio distributes holdings more evenly. Review PBE's holdings table to analyze concentration risk.
What is PBE's sector allocation?
The Sector Allocation chart shows how PBE distributes investments across different industries like Technology, Healthcare, Financials, and more. This sector exposure helps understand the fund's industry diversification strategy.
What countries does PBE invest in?
PBE's geographic exposure is shown in the Countries tab under Portfolio Allocations. This reveals the fund's international diversification and exposure to different regions and global markets.
How diversified is PBE ETF?
PBE's diversification can be assessed by reviewing its 33 holdings, sector allocation, and geographic exposure. A well-diversified ETF spreads investments across multiple securities, sectors, and regions to reduce concentration risk.